Haya Therapeutics Secures $65 Million Series A Funding to Advance HTX-001 Heart Failure Treatment

Haya Therapeutics obtained $65 million in Series A funding to advance the clinical development of their drug candidate, HTX-001, for heart failure treatment. The company intends to use the funding to accelerate the drug’s progress through clinical trials. The Series A funding round will allow Haya Therapeutics to focus on getting HTX-001 to patients. This drug is specifically being developed as a potential treatment option for individuals suffering from heart failure. The $65 million investment will directly support the clinical trials necessary to evaluate the safety and efficacy of HTX-001.

Newsflash | Powered by GeneOnline AI
Date: May 9, 2025

Related posts:

Breakthrough Study Suggests Common Antibiotic Vancomycin Could Treat Specific Inflammatory Bowel Disease Alzheimer’s Research: 16 New Susceptibility Genes Identified Trump Administration Asks Judge to Dismiss Lawsuit Seeking to Block Telehealth Access to Abortion Pill Mifepristone Regulatory and Payer Issues Hinder AI Integration in Pharmacy Operations, Experts Say.

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後